Frontlight ResearchEarly access
Not yet taking people in FrancePhase 1
Testing RUPISTAR in adults with advanced breast cancer that has an ESR1 mutation
Tests RUPISTAR in adults with advanced, hormone-sensitive breast cancer with an ESR1 mutation.
Key facts
- Who runs it
- Evexta Bio
- Where
- Lyon and Saint-Herblain Cedex, FranceSee the 2 sites
- Trial code
- Registry title
- RUPISTAR: A Study in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutation
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 6 people, planned
- Started
- 12 Nov 2026
- Expected to end
- 5 Mar 2028
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ER-positive, HER2-negative breast cancer that has spread or cannot be removed, and who have an ESR1 mutation.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- ER-positive, HER2-negative advanced or metastatic breast cancer
- Biomarker or test result
- An ESR1 mutation
Where in France
- Centre Leon BerardLyon, FranceNot yet recruiting
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Testing RUPISTAR in adults with advanced breast cancer that has an ESR1 mutationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 10 November 2026.
- Record updated
- 9 November 2026